A chemical biology approach to developing STAT inhibitors: Molecular strategies for accelerating clinical translation

Oncotarget

Volumn 2, Issue 6, 2011, Pages 518-524

  Nelson, Erik A ^a   Sharma, Sreenath V ^b,c   Settleman, Jeffrey ^b   Frank, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cancer therapy; Signal transduction; STAT transcription factors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NIFUROXAZIDE; PIMOZIDE; PROTEIN INHIBITOR; PYRIMETHAMINE; STAT PROTEIN INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; STAT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GILLES DE LA TOURETTE SYNDROME; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; PHENOTYPE; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; ADULT; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; METHODOLOGY; NEOPLASM; REVIEW; TIME; TRANSLATIONAL RESEARCH;

ADULT; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; STAT TRANSCRIPTION FACTORS; TIME FACTORS; TRANSLATIONAL RESEARCH;

EID: 80555149872     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.296     Document Type: Article

References (33)

1. Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription. lessons learned from STAT5. Cytokine Growth Factor Rev. 2004; 15:435-455.
2. Frank DA. STAT signaling in cancer. Insights into pathogenesis and treatment strategies. Cancer Treat Res. 2003; 115:267-291.
3. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC, Frank DA. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008; 112:5095-5102.
4. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010; 1:22-33.
5. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011; 117:3421-3429.
6. Shuai K, Halpern J, Ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996; 13:247-254.
7. Ye D, Wolff N, Li L, Zhang S, Ilaria RL, Jr. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood. 2006; 107:4917-4925.
8. Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. N Engl J Med. 2002; 346:683-693.
9. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011; 103:553-561.
10. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293:876-880.
11. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99:319-325.
12. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen. high efficacy of drug combinations. Blood. 2006; 108:2332-2338.
13. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009; 113:4052-4062.
14. Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N, Preudhomme C, Quesnel B. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia. 2008; 22:791-799.
15. Ito T, Tanaka H, Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol. 2007; 78:417-431.
16. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011; 117:3409-3420.
17. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005; 65:5054-5062.
18. Li Y, McClintick J, Zhong L, Edenberg HJ, Yoder MC, Chan RJ. Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4. Blood. 2004; 105:635-637.
19. Fukuda T, Yoshida T, Okada S, Hatano M, Miki T, Ishibashi K, Okabe S, Koseki H, Hirosawa S, Taniguchi M et al. Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med. 1997; 186:439-448.
20. Marotta LL et al. Signaling pathways required by CD44+/CD24- stem-cell-like breast cancer cells in human tumors. JCI. 2011; In press.
21. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. 2000; 2:86-90.
22. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009; 27:4422-4432.
23. Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW, Hiddemann W, Spiekermann K. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood. 2005; 105:3679-3685.
24. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther. 2008; 7:3169-3175.
25. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN et al. The Connectivity Map. using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313:1929-1935.
26. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007; 104:19936-19941.
27. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010; 10:241-253.
28. Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, Abernethy JL, Edington HD, Donnelly SS, Becker D. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999; 5:11-20.
29. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 2003; 22:7809-7818.
30. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A. 2000; 97:4227-4232.
31. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell. 2002; 2:5-7.
32. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma. a first step toward manageable disease. Clin Cancer Res. 2011; 17:1658-1663.
33. Corcoran RB, Settleman J, Engelman JA. Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. Oncotarget. 2011; 2:336-346.